Zoetis, Inc. Stock Plummets to New 52-Week Low of $112.11

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 112.11 as of May 4, 2026. This decline marks a significant downturn for the stock, which has experienced a 36.99% decrease in value over the past year, contrasting sharply with the S&P 500's performance of 26.63% during the same period. Despite the recent price drop, Zoetis maintains a robust market capitalization of USD 53,244 million and demonstrates strong financial metrics, including a price-to-earnings ratio of 20.00 and a commendable return on equity of 80.42%. The company has shown resilience with a healthy annual net sales growth rate of 8.16% and has reported positive results for the last six consecutive quarters. Zoetis also boasts a solid dividend yield of 1.71% and a low debt-to-EBITDA ratio of 1.22, indicating a strong ability to manage its debt obligations. While the stock's performance has been below par in both the long and near term, the company's operational efficiency and consistent cash flow generation remain noteworthy.